MLL(KMT2A) 11q23 Gene Rearrangement
Expected Turnaround Time
5 days
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Clinical Information
FISH test on hematologic specimens for detection of KMT2A (11q23 / MLL) gene rearrangement. KMT2A rearrangement may occur in a variety of neoplastic processes including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and pre-B acute lymphoblastic leukemia (ALL), Amplification of MLL (KMT2A) is a rare but recurrent finding in cases of both AML and B-ALL.
Requisition Forms
Specimen Requirements
Specimen Requirements
- Whole Blood: 5 mL, EDTA preferred (NaHep accepted)
- Bone Marrow Aspirate: 3 mL, EDTA preferred (NaHep accepted)
Specimen Stability
72 hours
Storage Requirements
- Whole Blood: 2°C to 25°C
- Bone Marrow Aspirate: 2°C to 25°C
- Fixed Cytogenetically Prepared Cells: -28°C to -15°C
Shipping Conditions
Ambient, Refrigerated
Shipping Recommendations
AMBIENT, Use a refrigerated (NOT FROZEN) gel pack in the shipment to protect from extreme temperatures. Separate gel pack from specimen. Do not freeze.
Specimen Rejection Criteria
Clotted specimen; Specimen exposed to extreme temperature; Anticoagulant toxic to cells; Insufficient number of cells
Test Details
Synonyms
Mixed lineage leukemia, 11q23, KMT2Ar, ALL1, CXXC7, HRX, HTRX, MLL, MLL1, TRX1
Keywords
Fluorescence in-situ Hybridization, Leukemia, Oncology, Oncology FISH Probes, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)
Test Method
Fluorescence in situ hybridization (FISH)
Methodology Category
FISH
Regulatory Status
ASR
Special Considerations
All attempts will be made to process and report samples received > 72 hours post-collection. Bone marrow is the sample of choice in most heme malignancies.
Associations
Acute myelogenous leukemia (AML), Acute lymphoblastic leukemia (ALL), HOX gene